1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. JW (Cayman) Therapeutics Co. Ltd
  6. News
  7. Summary
    2126   KYG5210T1040

JW (CAYMAN) THERAPEUTICS CO. LTD

(2126)
  Report
Delayed Hong Kong Stock Exchange  -  05/20 04:08:13 am EDT
7.200 HKD   +1.55%
04/25JW Therapeutics Announces Its Cell Immunotherapy Drugs Have Successfully Benefited 200 Chinese Patients
CI
04/20JW Therapeutics Announces IND Approval for the Clinical Trial of Carteyva® in Pediatric and Young Adult Patients
CI
04/04China's Drug Regulator Grants Breakthrough Therapy Designation for JW (Cayman) Therapeutics' Lymphoma Drug
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

JW Therapeutics Co. Ltd Announces Executive Changes

12/17/2021 | 03:38am EDT

The board of directors (the "Board") of JW (Cayman) Therapeutics Co. Ltd. (the "Company") hereby announced that Mr. Lee Kwok Fai Kenneth ("Mr. Lee") has resigned from his positions as the company secretary, the authorized representative (the "Authorized of the Company The Board is also pleased to announce that Ms. Ng Ka Man ("Ms. Ng") has been appointed by the Company as the company secretary, the Authorized Representative and the Process Agent in place of Mr. Lee, with effect from December 17, 2021.


© S&P Capital IQ 2021
All news about JW (CAYMAN) THERAPEUTICS CO. LTD
04/25JW Therapeutics Announces Its Cell Immunotherapy Drugs Have Successfully Benefited 200 ..
CI
04/20JW Therapeutics Announces IND Approval for the Clinical Trial of Carteyva® in Pediatric..
CI
04/04China's Drug Regulator Grants Breakthrough Therapy Designation for JW (Cayman) Therapeu..
MT
04/03JW Therapeutics Announces Receipt of Breakthrough Therapy Designation for Carteyva® in ..
CI
03/31JW Therapeutics Wins Nod to Start Clinical Trial in China of Immunotherapy for B-cell L..
MT
03/31JW Therapeutics Announces IND Approval for the Pivotal Clinical Trial of Carteyva® in S..
PR
03/31JW Therapeutics Announces IND Approval for the Pivotal Clinical Trial of Carteyva® in S..
CI
03/29UBS Adjusts JW Therapeutics' Price Target to HK$21 From HK$22, Keeps at Buy
MT
03/23JW Therapeutics Co. Ltd Reports Earnings Results for the Full Year Ended December 31, 2..
CI
02/27China Accepts JW (Cayman) Therapeutics' Supplemental New Drug Application for Follicula..
MT
More news
Analyst Recommendations on JW (CAYMAN) THERAPEUTICS CO. LTD
More recommendations
Financials
Sales 2022 167 M 24,9 M 24,9 M
Net income 2022 -881 M -132 M -132 M
Net cash 2022 769 M 115 M 115 M
P/E ratio 2022 -2,87x
Yield 2022 -
Capitalization 2 521 M 377 M 377 M
EV / Sales 2022 10,5x
EV / Sales 2023 3,74x
Nbr of Employees 534
Free-Float 55,8%
Chart JW (CAYMAN) THERAPEUTICS CO. LTD
Duration : Period :
JW (Cayman) Therapeutics Co. Ltd Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JW (CAYMAN) THERAPEUTICS CO. LTD
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 6,14 CNY
Average target price 14,09 CNY
Spread / Average Target 129%
EPS Revisions
Managers and Directors
Yi Ping Li Chairman & Chief Executive Officer
Xin Fu Chief Financial Officer & Senior Vice President
Lapyuen Harry Lam Chief Technology Officer & Executive VP
Shaun Paul Cordoba Chief Scientific Officer
Chi Shing Li Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
JW (CAYMAN) THERAPEUTICS CO. LTD-46.43%377
GILEAD SCIENCES, INC.-12.08%80 075
REGENERON PHARMACEUTICALS, INC.4.69%71 235
VERTEX PHARMACEUTICALS17.76%66 136
WUXI APPTEC CO., LTD.-16.92%42 735
BIONTECH SE-36.77%39 612